Results 211 to 220 of about 20,010 (263)

Androgen receptor activation promotes tumor progression in canine and human triple negative breast cancer cell lines. [PDF]

Front Vet Sci
Caceres S, Crespo B, Herrera M, de la Puente M, Diaz Del Arco C, Alonso-Diez A, Illera MJ, Illera JC.   +7 more
europepmc   +1 more source

Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study. [PDF]

BMJ Open
Chen ZJ, Zhu XX, Huang H, Ding YZ, Zhuang YD, Wang L, Li P, Yu KY, Chen HD, Wang HL, Li HY, Cai B, Deng ZX, Pan Y, Yang Y, Li P, Huang KT, Ji XW, Lin Q, Chen W.   +19 more
europepmc   +1 more source

Androgen receptor expression in glioblastoma: molecular profiling and association with tumor burden. [PDF]

Mol Biol Rep
Liubych L, Hahn L, Hollnagel R, Streubel MK, Ailani D, Leppert J, Krenzlin H, Matschke J, Soltwedel C, Borgardt N, Behling S, Zemskova O, Ditz C, Gebauer N, Kebenko M, Keric N, Lapshyna O, Gemoll T, Carl C, Neumann A, Rades D, Löser A.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recent Developments in Androgen Receptor Antagonists

Archiv der Pharmazie, 2015
The androgen receptor (AR), a ligand‐dependent transcription factor that regulates the expression of a series of downstream target genes after the binding of androgens, has been a target for the discovery of drugs used to treat prostate cancer. Prostate cancer always progresses to castration‐resistant prostate cancer after a period of androgen ...
Fansheng, Ran, Hualu, Xing, Yang, Liu, Daoguang, Zhang, Pengzhan, Li, Guisen, Zhao   +5 more
openaire   +4 more sources

The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2004
A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro.
Aaron, Balog, Mark E, Salvati, Weifang, Shan, Arvind, Mathur, Leslie W, Leith, Donna D, Wei, Ricardo M, Attar, Jieping, Geng, Cheryl A, Rizzo, Chihuei, Wang, Stanley R, Krystek, John S, Tokarski, John T, Hunt, Marco, Gottardis, Roberto, Weinmann   +14 more
openaire   +4 more sources

Androgen antagonists in androgen target tissues

Pharmacology & Therapeutics, 1984
Most antiandrogens appear to act by binding to the androgen receptor and competitively inhibiting the binding of testosterone and cihydrotestosterone to the receptor. Focusing on those compounds which appear to inhibit androgen receptor mediated responses this review discusses the chemistry of those antiandrogens which have been studied to the extent ...
D J, Tindall, C H, Chang, T J, Lobl, G R, Cunningham   +3 more
openaire   +2 more sources

Classification and Virtual Screening of Androgen Receptor Antagonists

Journal of Chemical Information and Modeling, 2010
Computational tools, such as quantitative structure-activity relationship (QSAR), are highly useful as screening support for prioritization of substances of very high concern (SVHC). From the practical point of view, QSAR models should be effective to pick out more active rather than inactive compounds, expressed as sensitivity in classification works.
Jiazhong Li, Paola Gramatica
openaire   +2 more sources

Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist

Expert Opinion on Pharmacotherapy, 2021
Introduction: Increased circulating androgens are key to the multifactorial pathogenesis of acne. Clascoterone is the first topical androgen antagonist developed to treat acne in both male and female patients and the first such agent to receive U.S. Food and Drug Administration (FDA) approval for treatment of acne.
openaire   +2 more sources